Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 12, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.93 · Expires 2029-06-12 | Direct | 5,834 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 5,834 · Balance 5,834 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 12, 2019 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 12, 2019 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2019 Filed Jun 14, 2019 20:54 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-19-037169 · doc4.xml · derivative · entry 1 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 12, 2019 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| January 28, 2019 Filed Jan 31, 2019 22:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006198 · doc4.xml · nonDerivative · entry 2 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 65,421 F1 · ownership.direct: The shares are held directly by The Glenn A. Oclassen 2016 Trust dated November 30, 2016 (the "Trust"). The Reporting Person serves as trustee of the Trust. Read SEC document |
| January 25, 2019 Filed Jan 31, 2019 22:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006198 · doc4.xml · nonDerivative · entry 1 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 140,421 F1 · ownership.direct: The shares are held directly by The Glenn A. Oclassen 2016 Trust dated November 30, 2016 (the "Trust"). The Reporting Person serves as trustee of the Trust. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 20:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | ConversionSeries A Convertible Preferred Stock · Derivative | 200,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038596 · doc4.xml · derivative · entry 2 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 200,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by The Glenn A. Oclassen 2016 Trust dated November 30, 2016 (the "Trust"). The Reporting Person serves as trustee of the Trust. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 20:48 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | ConversionCommon Stock | 200,734 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-038596 · doc4.xml · nonDerivative · entry 1 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 290,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by The Glenn A. Oclassen 2016 Trust dated November 30, 2016 (the "Trust"). The Reporting Person serves as trustee of the Trust. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:28 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 17,502 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038308 · doc4.xml · derivative · entry 1 OCLASSEN GLENN A · CIK 0001210529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2028-06-14 F1 · derivative.exercise_date: 1/3 of the total shares subject to the option shall vest on June 14, 2019 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.